Ultragenyx UK

Fluconazole (APO-FLUCONAZOLE) is a small-molecule antifungal agent being developed by Ultragenyx UK Limited for the treatment of histoplasmosis. The drug is administered via injection and represents a repurposing of an established antifungal compound. The program, identified by internal code 199/12010, completed Phase 2 clinical evaluation as of June 2006. Fluconazole is already approved in multiple markets including the United States and Australia, where it is marketed by numerous generic and branded manufacturers. The Phase 2 histoplasmosis program represents a targeted indication development strategy for an existing therapeutic agent. The latest disclosed milestone occurred on 9 June 2006, with no subsequent milestones or expected catalysts disclosed in available records. Regulatory approvals for fluconazole in its generic forms span multiple decades, with Australian approvals dating to 1994 and US approvals documented across numerous abbreviated new drug applications (ANDAs) and new drug applications (NDAs).

Histoplasmosis is a serious systemic fungal infection caused by Histoplasma capsulatum, endemic in certain geographic regions and presenting significant morbidity and mortality in immunocompromised populations, particularly those with advanced HIV/AIDS. The disease remains a substantial clinical burden in endemic areas, with limited treatment options and variable clinical outcomes depending on disease severity and host immune status. Fluconazole represents an established antifungal therapeutic with a well-characterized safety and efficacy profile, offering potential advantages in treating histoplasmosis through a parenteral route of administration. The competitive landscape includes itraconazole, another azole antifungal also in Phase 2 development by Ultragenyx UK Limited for related indications. The commercial significance of histoplasmosis treatment remains modest compared to other fungal infections, but the indication addresses an unmet need in endemic regions and immunocompromised patient populations. The existing regulatory approvals for fluconazole across multiple jurisdictions and manufacturers indicate established manufacturing and distribution infrastructure, potentially facilitating rapid market access if the Phase 2 program achieves positive efficacy and safety outcomes.

Drug Class: Azole antifungal (small-molecule)

Modality: Small molecule

Route of Administration: Injection (intravenous)

Mechanism of Action: Not yet disclosed in available program documentation

Molecular Target: Not yet disclosed in available program documentation

Brand Name: APO-FLUCONAZOLE

Related Therapies: Itraconazole (Phase 2, Ultragenyx UK Limited); other azole antifungals approved for systemic fungal infections

Regulatory Status:

• United States: Approved (multiple ANDA and NDA approvals documented; marketed by 31+ manufacturers including Pfizer, Teva, Mylan, Baxter, Hospira, Fresenius Kabi, and others)
• Australia: Approved (PBS-listed; first approvals 1994-08-01 and 1994-10-01; marketed by Apotex, Arrotex, Arrow Pharma, Pfizer Australia, Sandoz)

Patent Status: Not yet disclosed

United States Regulatory Status: Fluconazole is approved via multiple abbreviated new drug applications (ANDAs) and new drug applications (NDAs). Documented application numbers include NDA019949, NDA019950, NDA020090, and 42 ANDAs (ANDA074681 through ANDA218692). Approved sponsors include ANI Pharma, Aurobindo Pharma, Baxter Healthcare, Chartwell, Dr. Reddy's Labs, FDC Ltd, Fresenius Kabi USA, Gedeon Richter USA, Glenmark Pharma, Hikma, Hospira, Inforlife, IVAX/Teva, Lupin, Mylan, Pfizer, Pharmobedient, PLIVA, Ranbaxy Labs, Roxane, Sun Pharma, Taro Pharma, Teva, Unique, Woodward, and Zhejiang Poly Pharma.

Australia Regulatory Status: Fluconazole is approved and PBS-listed with codes 1471K, 1472L, 1475P, and 5446P. First listed dates: 1994-08-01, 1994-10-01, and 2006-12-01. Approved sponsors include Apotex Pty Ltd, Arrotex Pharmaceuticals Pty Ltd, Arrow Pharma Pty Ltd, Pfizer Australia Pty Ltd, and Sandoz Pty Ltd.

EMA, PMDA (Japan), NMPA (China) Status: Not yet disclosed in available program documentation.

Histoplasmosis Indication: Regulatory approval status for the specific histoplasmosis indication is not yet disclosed; the Phase 2 program remains in clinical development.

Strategic Implications: Ultragenyx UK Limited's development of fluconazole for histoplasmosis represents a targeted indication-expansion strategy for an established antifungal compound. The Phase 2 completion milestone in June 2006 suggests the program advanced beyond early clinical stages, though the absence of subsequent disclosed milestones over 18+ years raises questions regarding program status and commercial prioritization. The lack of disclosed efficacy, safety, or regulatory pathway information limits assessment of competitive positioning and commercial viability.

Competitive Positioning: Fluconazole's extensive prior regulatory approvals and established manufacturing infrastructure across 31+ US manufacturers and multiple international suppliers provide significant competitive advantages in terms of supply chain maturity, regulatory familiarity, and cost structure compared to novel antifungal candidates. However, the Phase 2 status and absence of recent milestones suggest the histoplasmosis indication may not represent a primary commercial focus for Ultragenyx.

Future Catalysts: Potential catalysts include Phase 2 efficacy and safety data disclosure, Phase 3 initiation (if planned), regulatory feedback on indication-specific approval pathways, and commercial partnership announcements. The 18-year gap since the last disclosed milestone (June 2006) suggests the program may be inactive, discontinued, or deprioritized.

Expected Milestones: No expected milestones are disclosed in available program documentation.